Key clinical point: The phosphoinositide 3-kinase–delta inhibitor ME-401 produced a high overall response rate in patients with relapsed or refractory follicular lymphoma.

Major finding: The overall response rate was 80% for the entire cohort, 79% in patients who received ME-401 alone, and 83% in those who received ME-401 plus rituximab.

Study details: A phase 1b trial of 54 patients with relapsed/refractory follicular lymphoma.

Disclosures: The study is sponsored by MEI Pharma. The investigators reported relationships with MEI Pharma and several other companies.